welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Cancer Prevention Pharmaceuticals Completes Target Enrollment in Pivotal Phase 3 Clinical Trial Evaluating CPP-1X/sulindac in Patients with Familial Adenomatous Polyposis
Cancer Prevention Pharmaceuticals, Inc. (CPP), a private biotech company developing novel therapeutics to prevent cancer and other diseases, announced today that target enrollment has been achieved for the company’s pivotal Phase 3 clinical trial, CPP FAP-310, evaluating CPP-1X/sulindac in adults with familial adenomatous polyposis (FAP).
expertly curated content related to this topic
-
Long-Term Outcome of Sporadic and FAP-Associated Desmoid Tumors Treated with High-Dose Selective Estrogen Receptor M...Aim of this study is to evaluate the out...
-
Selective COX-2 Inhibition Affects Fatty Acids, but not COX mRNA Expression in Patients with FAPFamilial adenomatous polyposis (FAP) pro...
-
Nutritional Agents With Anti-inflammatory Properties in Chemoprevention of Colorectal NeoplasiaThe strong link between inflammation and...
-
BCIR – Olympia Medical Center Los Angeleshttps://www.youtube.com/channel/UCEdZLy_...
-
Registry With Information About Colitis Ulcerosa and Familial Adenomatous Polyposis PatientsThe purpose of this registry is to colle...